VIDA is dedicated to providing the most clinically validated solution for the quantitative assessment of pulmonary disease.
Validated in over 25,000 exams in comprehensive clinical trials, VIDA is the most comprehensively tested solution available today.
Read more on PW2>>
VIDA Diagnostics is a leader in quantitative pulmonary image analysis for the diagnosis and treatment of pulmonary diseases.
The FDA-cleared Pulmonary Workstation 2.0 (PW2) is the leading lung analysis tool for COPD, emphysema and asthma. Participating in the emerging pulmonary device market that is expected to grow to nearly $3.8 billion by 2011, VIDA’s vision is to establish lung quantitative CT methods as the standard of care for diagnosis and staging of chronic lung disease.
Founded by four University of Iowa faculty members, Eric Hoffman, Ph.D., Geoffrey McLennan, M.D., Ph.D., Joseph Reinhardt, Ph.D and, Milan Sonka, Ph.D., VIDA Diagnostics is based on research associated with the UI’s Iowa Comprehensive Lung Imaging Center directed by Dr. Hoffman and on core technology licensed from the UI Research Foundation.
NEWS
11.09.09 - VIDA DIAGNOSTICS AND VERAN MEDICAL SIGN DEFINITIVE AGREEMENT FOR JOINT DEVELOPMENT OF ENDOBRONCHIAL NAVIGATION SYSTEM Read Press Release >>
See us at Radiological Society of North America (RSNA) 95th Annual Meeting in Chicago, IL. November 27 - Dec 2, 2009Booth 1406 Lakeside Center - Hall D
09.27.09 - VIDA Diagnostics Appoints Thoracic Imaging Innovator Susan A. Wood, Ph.D., as President and CEO Read Press Release >>
